Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From…

StudyCancer medicine· Sep 2025

Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.

Ida Russo, Valentina Di Ruscio, Maria Antonietta De Ioris … Franco Locatelli

Ocular OncologyStudyTreatmentQ1IF 3.6

Eye overall survival was 48.9% at 5 years in high-risk retinoblastoma eyes.

Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.

Ida Russo … Franco Locatelli

Cancer medicine · Sep 2025

Background

This study presents the outcomes of high-risk group retinoblastoma (Rb) patients enrolled in the AIEOP RTB 012 Protocol.

Methods

With intraocular unilateral Rb classified as group C/D according to "International Intraocular Retinoblastoma Classification" (IIRC), as well as those with bilateral Rb with at least one eye group C/D/E-IIRC, were treated with four cycles of carboplatin/etoposide combined with focal treatments.

n = 88 eyes

Results

less than half of these high-risk eyes were saved after 5 years

100%

Group A/B

73.3%

Group C

42.5%

Group D

14.3%

Group E

More results

The 2- and 5-year eye event-free survival rates were 31.1% (95% CI: 24.4-44.0) and 29.5% (95% CI: 20.4-39.2), respectively.

More results

Ocular survival significantly differed across IIRC groups, with 2- and 5-year survival rates of 100% for group A/B, 86.7% and 73.3% for group C, 65% and 42.5% for group D, and 23.8% and 14.3% for group E, respectively (p < 0.05).

No severe toxicity was reported.

“

Conclusion

The AIEOP RTB 012 protocol has proven to be both safe and effective, ensuring a favorable final visual acuity.

Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.

Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.

Related papers